Moleculin Biotech, Inc. 8-K

What Happened Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on February 18, 2026 (Accession: 0001437749-26-004558) under Item 7.01 (Regulation FD Disclosure) to announce that it is using an updated corporate investor presentation. The presentation is dated February 2026, has been posted on the company’s website, and is included in the filing as Exhibit 99.1.

Key Details

• Filing date: February 18, 2026; Form 8-K filed under Item 7.01 (Regulation FD Disclosure).
• Exhibit included: 99.1 — Investor Presentation dated February 2026 (also posted on the company website).
• Item 9.01 exhibits list includes Exhibit 99.1 and the Inline XBRL cover page (Exhibit 104).
• The filing does not report earnings, financial results, executive changes, or other material events beyond the presentation disclosure.

Why It Matters This 8-K informs investors that Moleculin has publicly distributed an updated investor presentation and satisfied Regulation FD disclosure requirements, ensuring the information is broadly available. Investors should review the attached presentation for the company’s latest strategic messaging, pipeline updates, milestones or timelines; however, the filing itself does not provide new financial results or governance changes.